Posted by Michael Wonder on 08 Feb 2018
Once a day pill for ovarian cancer could be made available on the CDF
8 February 2018 - NICE has invited Tesaro to submit a proposal for including niraparib (Zejula) in the Cancer Drugs Fund (CDF), for treating some types of recurrent ovarian cancer.
According to company estimates up to 850 women in England and Wales could benefit from this new treatment.
In this draft guidance niraparib was appraised for the treatment of women with relapsed ovarian, fallopian tube and peritoneal cancer who have had 2 or more courses of platinum based chemotherapy.
